Journal of the American College of Cardiology
State-of-the-Art PaperRelevant Issues in the Pathology and Pathobiology of Pulmonary Hypertension
Key Words
Abbreviations and Acronyms
Cited by (0)
Dr. Tuder is supported by the Cardiovascular Medical Research and Education Fund and RC1 HL 10084. Dr. Dorfmüller has received speaker fees for meetings supported by Actelion Pharmaceuticals. Dr. Erzurum is supported by NIH-RO1-HL071115, 1RC1HL099462SLAHL115008, and HL60917. Dr. Guignabert is supported by the French National Agency for Research ANR_12_JSV1_0004_01. Dr. Michelakis has served on steering committees for Medtelligence (Young Investigators Selection Committee) and Bayer (Clinical Trial Steering Committee), both of which totaled <$10,000 in the past 2 years. Dr. Schermuly is supported by LOEWE Center Universities of Giessen and Marburg Lung Center (UGMLC-LOEWE), Excellence Cluster Cardio-Pulmonary System (ECCPS), and German Center for Lung Research (DZL); and has received research grants from Actelion, Bayer-Healthcare, Novartis, Noxxon, and Pfizer. Dr. Stenmark is supported by NIH/NHLBI Axis Grant, 1R01HL114887, NIH PPG 5P01HL014985, and NIH/NHLBI SCCOR 5P50HL084923; and has received unrestricted research grants from Actelion, Bayer-Healthcare, Novartis, Noxxon, and Pfizer. Dr. Morrell is supported by NIHR Cambridge Biomedical Research Centre and the British Heart Foundation (BHF). All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. Drs. Tuder and Morrell are joint corresponding authors.